Skip to Main Content

Author Details

Matthew L Freedman
Dana-Farber Cancer Institute
1993
184
62
PMIDPaper TitleJournal TitlePublished Year
36681680Epigenomic charting and functional annotation of risk loci in renal cell carcinoma.Nat Commun2023
36399432Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes.Cancer Discov2023
37857693Author Correction: A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus.Nat Commun2023
38057321The PENGUIN approach to reconstruct protein interactions at enhancer-promoter regions and its application to prostate cancer.Nat Commun2023
37865722Liquid biopsy epigenomic profiling for cancer subtyping.Nat Med2023
37612286A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus.Nat Commun2023
37090516Rewiring of master transcription factor cistromes during high-grade serous ovarian cancer development.bioRxiv2023
37271632Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.Eur Urol2023
36546757Optimized high-throughput screening of non-coding variants identified from genome-wide association studies.Nucleic Acids Res2023
36993558Analysis of evolutionary dynamics and clonal architecture in prostate cancer.bioRxiv2023
36681680Epigenomic charting and functional annotation of risk loci in renal cell carcinoma.Nat Commun2023
37038004Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer.Nat Cancer2023
37865722Liquid biopsy epigenomic profiling for cancer subtyping.Nat Med2023
37857693Author Correction: A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus.Nat Commun2023
38057321The PENGUIN approach to reconstruct protein interactions at enhancer-promoter regions and its application to prostate cancer.Nat Commun2023
37612286A biallelic multiple nucleotide length polymorphism explains functional causality at 5p15.33 prostate cancer risk locus.Nat Commun2023
37090516Rewiring of master transcription factor cistromes during high-grade serous ovarian cancer development.bioRxiv2023
36993558Analysis of evolutionary dynamics and clonal architecture in prostate cancer.bioRxiv2023
37038004Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer.Nat Cancer2023
37271632Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.Eur Urol2023
36546757Optimized high-throughput screening of non-coding variants identified from genome-wide association studies.Nucleic Acids Res2023
36399432Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes.Cancer Discov2023
34907080Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis.Clin Cancer Res2022
36103646Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer.JCO Precis Oncol2022
35509021Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer.Clin Epigenetics2022
35754340Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.Cancer Discov2022
35943799Patterns of structural variation define prostate cancer across disease states.JCI Insight2022
35562350MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets.Nat Commun2022
35492879A multi-level investigation of the genetic relationship between endometriosis and ovarian cancer histotypes.Cell Rep Med2022
36210504Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci.J Natl Cancer Inst2022
36071171Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation.Nat Genet2022
35731919The Prostate Cancer Androgen Receptor Cistrome in African American Men Associates with Upregulation of Lipid Metabolism and Immune Response.Cancer Res2022
35550030CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies.Elife2022
35477723ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer.Nat Commun2022
35603787Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome.JCI Insight2022
36450752Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.Nat Commun2022
35468964HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer.Nat Genet2022
36526723Germline variants associated with toxicity to immune checkpoint blockade.Nat Med2022
36526722IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.Nat Med2022
34907080Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis.Clin Cancer Res2022
35550030CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor-targeting therapies.Elife2022
35509021Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer.Clin Epigenetics2022
35477723ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer.Nat Commun2022
35731919The Prostate Cancer Androgen Receptor Cistrome in African American Men Associates with Upregulation of Lipid Metabolism and Immune Response.Cancer Res2022
35468964HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer.Nat Genet2022
35603787Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome.JCI Insight2022
35492879A multi-level investigation of the genetic relationship between endometriosis and ovarian cancer histotypes.Cell Rep Med2022
35754340Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.Cancer Discov2022
35562350MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets.Nat Commun2022
36526723Germline variants associated with toxicity to immune checkpoint blockade.Nat Med2022
  • 1 - 50 of 368

Recommended Authors

Xiaoyu Wang
Fred Hutchison Cancer Center
Career Start Year 2015
Number of shared co-authors 13
Matthew H Bailey
Department of Biology at Brigham Young University
Career Start Year 2013
Number of shared co-authors 5
Aurelie Vogt
Frederick National Laboratory for Cancer Research (FNLCR), Inc.
Career Start Year 2012
Number of shared co-authors 24
Burcu F Darst
Fred Hutchinson Cancer Center
Career Start Year 2011
Number of shared co-authors 62
Sander Canisius
The Netherlands Cancer Institute
Career Start Year 2011
Number of shared co-authors 66
Paul Lloyd
Bluestar Genomics Inc.
Career Start Year 2010
Number of shared co-authors 26
Sebastian M Armasu
Division of Clinical Trials and Biostatistics, Mayo Clinic
Career Start Year 2009
Number of shared co-authors 97
Lincoln D Stein
Ontario Institute for Cancer Research
Career Start Year 2009
Number of shared co-authors 39
Brandy Klotzle
Departments of Bioinformatics and Clinical Genomics, Illumina Inc.
Career Start Year 2009
Number of shared co-authors 9
Jinyoung Byun
Institute for Clinical and Translational Research, Baylor College of Medicine
Career Start Year 2009
Number of shared co-authors 74
Alessandro Romanel
University of Trento
Career Start Year 2008
Number of shared co-authors 16
Laurie Burdett
National Cancer Institute, Frederick National Laboratory for Cancer Research
Career Start Year 2005
Number of shared co-authors 44
Gong-Hong Wei
Fudan University Shanghai Cancer
Career Start Year 2004
Number of shared co-authors 21
Mine S Cicek
Mayo Clinic
Career Start Year 2004
Number of shared co-authors 85
Joachim Weischenfeldt
University of Copenhagen
Career Start Year 2004
Number of shared co-authors 24
Olivier Harismendy
University of California
Career Start Year 2003
Number of shared co-authors 5
Jianmin Wang
Roswell Park Comprehensive Cancer Center
Career Start Year 2003
Number of shared co-authors 10
Charlie E Massie
University of Cambridge
Career Start Year 2003
Number of shared co-authors 24
Andrew D Skol
The University of Chicago
Career Start Year 2001
Number of shared co-authors 22
Andrea Sboner
Institute for Computational Biomedicine
Career Start Year 2000
Number of shared co-authors 64
Hugues Sicotte
Mayo Clinic
Career Start Year 1999
Number of shared co-authors 51
Franklin W Huang
Institute for Human Genetics, University of California san francisco
Career Start Year 1998
Number of shared co-authors 51
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 35
Liang Wang
H. Lee Moffitt Cancer Center
Career Start Year 1996
Number of shared co-authors 34
John V Pearson
QIMR Berghofer Medical Research Institute
Career Start Year 1996
Number of shared co-authors 46
Carolyn M Hutter
National Human Genome Research Institute, National Institutes of Health
Career Start Year 1995
Number of shared co-authors 43
Arul M Chinnaiyan
University of Michigan Medical School.
Career Start Year 1993
Number of shared co-authors 85
Colin C Collins
University of British Columbia
Career Start Year 1988
Number of shared co-authors 74
Francesca Demichelis
University of Trento
Career Start Year 1969
Number of shared co-authors 63
Kelly A Frazer
University of California, USA Institute for Genomic Medicine
Career Start Year 1967
Number of shared co-authors 20

Collaborators

Mark M Pomerantz
Dana-Farber Cancer Institute
Co-authored papers 61
Christopher A Haiman
University of Southern California
Co-authored papers 40
Brian E Henderson
University of Southern California
Co-authored papers 36
Loic Le Marchand
Co-authored papers 25
Peter Kraft
Harvard T. H. Chan School of Public Health
Co-authored papers 25
Kathryn L Penney
Co-authored papers 24
Simon A Gayther
Cedars-Sinai Medical Center
Co-authored papers 23
Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 23
Daniel O Stram
Co-authored papers 22
Qiyuan Li
National Institute of Data Science in Health and Medicine, Xiamen University
Co-authored papers 22
David J Hunter
The Kolling Institute, University of Sydney, and Royal North Shore Hospital
Co-authored papers 22
Stephen J Chanock
National Cancer Institute, National Institutes of Health
Co-authored papers 21
Sylvan C Baca
Co-authored papers 21
Laurence N Kolonel
Co-authored papers 21
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Co-authored papers 21
Douglas F Easton
University of Cambridge
Co-authored papers 19
Toni K Choueiri
Dana-Farber Cancer Institute
Co-authored papers 17
David Altshuler
Broad Institute of Harvard and Massachusetts Institute of Technology (MIT)
Co-authored papers 17
Meir J Stampfer
Brigham and Women's Hospital
Co-authored papers 17
Demetrius Albanes
Co-authored papers 15
Malcolm C Pike
Memorial Sloan-Kettering Cancer Center
Co-authored papers 15
Cezary Cybulski
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 14
Wei Zheng
Co-authored papers 14
Lorelei A Mucci
Co-authored papers 14
Edward L Giovannucci
Harvard T.H. Chan School of Public Health
Co-authored papers 14
Beth Y Karlan
David Geffen School of Medicine, University of California los angeles
Co-authored papers 14
Elio Riboli
Co-authored papers 13
Fredrick R Schumacher
Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine
Co-authored papers 13
Connor Bell
Dana-Farber Cancer Institute
Co-authored papers 13
Joel N Hirschhorn
Broad Institute of MIT and Harvard
Co-authored papers 13
Release 1.2